Publication | Closed Access

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Her2-positive GastricGastrointestinal OncologyInterim AnalysesMedicineGastroenterologyPathologyCancer TreatmentOncologyRadiation OncologyPhase 3